Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru
Access to nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line antiretroviral therapy (ART) for HIV has been increasing in Peru since a national ART program was initiated in 2004. Between 2007 and 2009, we found a 1% prevalence of pr...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2018
|
| Materias: | |
| Acceso en línea: | Ver en el sistema de origen Ver en el sistema de origen Enlace permanente (DOI o Handle) |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1881508926394990592 |
|---|---|
| author | Jaime Soria Raquel Mugruza Molly Levine Segundo R. León Jorge Arévalo Eduardo Ticona Ingrid A. Beck Lisa M. Frenkel |
| author_browse | Eduardo Ticona Ingrid A. Beck Jaime Soria Jorge Arévalo Lisa M. Frenkel Molly Levine Raquel Mugruza Segundo R. León |
| author_facet | Jaime Soria Raquel Mugruza Molly Levine Segundo R. León Jorge Arévalo Eduardo Ticona Ingrid A. Beck Lisa M. Frenkel |
| author_sort | Jaime Soria |
| collection | Producción científica |
| description | Access to nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line antiretroviral therapy (ART) for HIV has been increasing in Peru since a national ART program was initiated in 2004. Between 2007 and 2009, we found a 1% prevalence of pre-ART HIV drug resistance (PDR) among antiretroviral (ARV)-naive Peruvians. Given that PDR has been associated with virologic failure (VF) of ART, in 2014-2015 we enrolled a follow-up cohort at the same institution to determine whether the rate of transmitted resistance had increased and compared virologic outcomes of those with and without PDR. Blood specimens from ARV-naive individuals were assessed for PDR to NNRTI-based ART by an oligonucleotide ligation assay (OLA) sensitive to 2% mutant within an individual's HIV quasispecies at reverse transcriptase codons M41L, K65R, K103N, Y181C, M184V, and G190A, and by Sanger consensus sequencing (CS). Rates of VF (plasma HIV RNA >200 copies/mL) were compared between those with and without PDR. Among 122 ARV-naive adults, PDR was detected by OLA in 17 (13.9%) adults. Compared with the 2007-2009 cohort, the proportion with PDR at OLA codons was significantly increased (p < .001). A total of 11 of 19 OLA mutations conferring high-level drug resistance were also detected by CS, and 8 additional participants had mutations encoding low-level resistance detected by CS for a total of 25 participants (20.5%). VF at month 6 of NNRTI-ART appeared greater in participants with versus without PDR [4/18 (22.2%) vs. 3/71 (4.2%); p = .03]. An increasing prevalence of PDR was detected among ARV-naive Peruvians. Studies are needed to determine risks of specific PDR mutations. |
| format | Article |
| id | oai:cris.upeu.edu.pe:20.500.15037/925 |
| institution | UPeU |
| language | English |
| publishDate | 2018 |
| publishDateRange | 2018 |
| publishDateSort | 2018 |
| record_format | dspace |
| spelling | oai:cris.upeu.edu.pe:20.500.15037/9252026-10-30T16:14:59ZPretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in PeruJaime SoriaRaquel MugruzaMolly LevineSegundo R. LeónJorge ArévaloEduardo TiconaIngrid A. BeckLisa M. FrenkelResistance mutationVirologyReverse transcriptaseMedicineReverse-transcriptase inhibitorDrug resistanceNucleoside Reverse Transcriptase InhibitorCohortViral loadZidovudineHIV drug resistanceStavudineDolutegravirViral quasispeciesAntiretroviral therapyInternal medicineHuman immunodeficiency virus (HIV)BiologyVirusPolymerase chain reactionViral diseaseGeneticsHepatitis C virusGeneResistance mutationVirologyReverse transcriptaseMedicineReverse-transcriptase inhibitorDrug resistanceNucleoside Reverse Transcriptase InhibitorCohortViral loadZidovudineHIV drug resistanceStavudineDolutegravirViral quasispeciesAntiretroviral therapyInternal medicineHuman immunodeficiency virus (HIV)BiologyVirusPolymerase chain reactionViral diseaseGeneticsHepatitis C virusAdolescentAdolescentAdolescentAdultAdultAdultFemaleFemaleFemaleGenes, ViralGenes, ViralGenes, ViralGenotypeGenotypeGenotypeHumansHumansHumansMaleMaleMaleMiddle AgedMiddle AgedMiddle AgedMutationMutationMutationPeruPeruPeruRisk FactorsRisk FactorsRisk FactorsHIV-1 drug effectsHIV-1 drug effectsHIV-1 drug effectsHIV-1 geneticsHIV-1 geneticsHIV-1 geneticsHIV Infections bloodHIV Infections bloodHIV Infections bloodHIV Infections drug therapyHIV Infections drug therapyHIV Infections drug therapyHIV Infections virologyHIV Infections virologyHIV Infections virologyTreatment OutcomeTreatment OutcomeTreatment OutcomeAnti-HIV Agents therapeutic useAnti-HIV Agents therapeutic useAnti-HIV Agents therapeutic useViral LoadViral LoadViral LoadDrug Resistance, ViralDrug Resistance, ViralDrug Resistance, ViralAnti-Retroviral AgentsAnti-Retroviral AgentsAnti-Retroviral AgentsYoung AdultYoung AdultYoung AdultHealth Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatmentLife Sciences Immunology and Microbiology Virology HIV Research and TreatmentHealth Sciences Medicine Infectious Diseases HIV/AIDS Research and InterventionsAccess to nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line antiretroviral therapy (ART) for HIV has been increasing in Peru since a national ART program was initiated in 2004. Between 2007 and 2009, we found a 1% prevalence of pre-ART HIV drug resistance (PDR) among antiretroviral (ARV)-naive Peruvians. Given that PDR has been associated with virologic failure (VF) of ART, in 2014-2015 we enrolled a follow-up cohort at the same institution to determine whether the rate of transmitted resistance had increased and compared virologic outcomes of those with and without PDR. Blood specimens from ARV-naive individuals were assessed for PDR to NNRTI-based ART by an oligonucleotide ligation assay (OLA) sensitive to 2% mutant within an individual's HIV quasispecies at reverse transcriptase codons M41L, K65R, K103N, Y181C, M184V, and G190A, and by Sanger consensus sequencing (CS). Rates of VF (plasma HIV RNA >200 copies/mL) were compared between those with and without PDR. Among 122 ARV-naive adults, PDR was detected by OLA in 17 (13.9%) adults. Compared with the 2007-2009 cohort, the proportion with PDR at OLA codons was significantly increased (p < .001). A total of 11 of 19 OLA mutations conferring high-level drug resistance were also detected by CS, and 8 additional participants had mutations encoding low-level resistance detected by CS for a total of 25 participants (20.5%). VF at month 6 of NNRTI-ART appeared greater in participants with versus without PDR [4/18 (22.2%) vs. 3/71 (4.2%); p = .03]. An increasing prevalence of PDR was detected among ARV-naive Peruvians. Studies are needed to determine risks of specific PDR mutations.Articlehttps://pubmed.ncbi.nlm.nih.gov/30560685https://www.ncbi.nlm.nih.gov/pmc/articles/636039410.1089/aid.2018.0239https://hdl.handle.net/20.500.15037/925W2905503184enAIDS Research and Human Retroviruses0889-22291931-84052018-12-182026-06-13T09:40:38Z2026-06-13T09:40:38Z |
| spellingShingle | Resistance mutation Virology Reverse transcriptase Medicine Reverse-transcriptase inhibitor Drug resistance Nucleoside Reverse Transcriptase Inhibitor Cohort Viral load Zidovudine HIV drug resistance Stavudine Dolutegravir Viral quasispecies Antiretroviral therapy Internal medicine Human immunodeficiency virus (HIV) Biology Virus Polymerase chain reaction Viral disease Genetics Hepatitis C virus Gene Resistance mutation Virology Reverse transcriptase Medicine Reverse-transcriptase inhibitor Drug resistance Nucleoside Reverse Transcriptase Inhibitor Cohort Viral load Zidovudine HIV drug resistance Stavudine Dolutegravir Viral quasispecies Antiretroviral therapy Internal medicine Human immunodeficiency virus (HIV) Biology Virus Polymerase chain reaction Viral disease Genetics Hepatitis C virus Adolescent Adolescent Adolescent Adult Adult Adult Female Female Female Genes, Viral Genes, Viral Genes, Viral Genotype Genotype Genotype Humans Humans Humans Male Male Male Middle Aged Middle Aged Middle Aged Mutation Mutation Mutation Peru Peru Peru Risk Factors Risk Factors Risk Factors HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV-1 genetics HIV-1 genetics HIV-1 genetics HIV Infections blood HIV Infections blood HIV Infections blood HIV Infections drug therapy HIV Infections drug therapy HIV Infections drug therapy HIV Infections virology HIV Infections virology HIV Infections virology Treatment Outcome Treatment Outcome Treatment Outcome Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Viral Load Viral Load Viral Load Drug Resistance, Viral Drug Resistance, Viral Drug Resistance, Viral Anti-Retroviral Agents Anti-Retroviral Agents Anti-Retroviral Agents Young Adult Young Adult Young Adult Health Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatment Life Sciences Immunology and Microbiology Virology HIV Research and Treatment Health Sciences Medicine Infectious Diseases HIV/AIDS Research and Interventions Jaime Soria Raquel Mugruza Molly Levine Segundo R. León Jorge Arévalo Eduardo Ticona Ingrid A. Beck Lisa M. Frenkel Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru |
| title | Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru |
| title_full | Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru |
| title_fullStr | Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru |
| title_full_unstemmed | Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru |
| title_short | Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru |
| title_sort | pretreatment hiv drug resistance and virologic outcomes to first line antiretroviral therapy in peru |
| topic | Resistance mutation Virology Reverse transcriptase Medicine Reverse-transcriptase inhibitor Drug resistance Nucleoside Reverse Transcriptase Inhibitor Cohort Viral load Zidovudine HIV drug resistance Stavudine Dolutegravir Viral quasispecies Antiretroviral therapy Internal medicine Human immunodeficiency virus (HIV) Biology Virus Polymerase chain reaction Viral disease Genetics Hepatitis C virus Gene Resistance mutation Virology Reverse transcriptase Medicine Reverse-transcriptase inhibitor Drug resistance Nucleoside Reverse Transcriptase Inhibitor Cohort Viral load Zidovudine HIV drug resistance Stavudine Dolutegravir Viral quasispecies Antiretroviral therapy Internal medicine Human immunodeficiency virus (HIV) Biology Virus Polymerase chain reaction Viral disease Genetics Hepatitis C virus Adolescent Adolescent Adolescent Adult Adult Adult Female Female Female Genes, Viral Genes, Viral Genes, Viral Genotype Genotype Genotype Humans Humans Humans Male Male Male Middle Aged Middle Aged Middle Aged Mutation Mutation Mutation Peru Peru Peru Risk Factors Risk Factors Risk Factors HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV-1 genetics HIV-1 genetics HIV-1 genetics HIV Infections blood HIV Infections blood HIV Infections blood HIV Infections drug therapy HIV Infections drug therapy HIV Infections drug therapy HIV Infections virology HIV Infections virology HIV Infections virology Treatment Outcome Treatment Outcome Treatment Outcome Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Viral Load Viral Load Viral Load Drug Resistance, Viral Drug Resistance, Viral Drug Resistance, Viral Anti-Retroviral Agents Anti-Retroviral Agents Anti-Retroviral Agents Young Adult Young Adult Young Adult Health Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatment Life Sciences Immunology and Microbiology Virology HIV Research and Treatment Health Sciences Medicine Infectious Diseases HIV/AIDS Research and Interventions |
| topic_facet | Resistance mutation Virology Reverse transcriptase Medicine Reverse-transcriptase inhibitor Drug resistance Nucleoside Reverse Transcriptase Inhibitor Cohort Viral load Zidovudine HIV drug resistance Stavudine Dolutegravir Viral quasispecies Antiretroviral therapy Internal medicine Human immunodeficiency virus (HIV) Biology Virus Polymerase chain reaction Viral disease Genetics Hepatitis C virus Gene Resistance mutation Virology Reverse transcriptase Medicine Reverse-transcriptase inhibitor Drug resistance Nucleoside Reverse Transcriptase Inhibitor Cohort Viral load Zidovudine HIV drug resistance Stavudine Dolutegravir Viral quasispecies Antiretroviral therapy Internal medicine Human immunodeficiency virus (HIV) Biology Virus Polymerase chain reaction Viral disease Genetics Hepatitis C virus Adolescent Adolescent Adolescent Adult Adult Adult Female Female Female Genes, Viral Genes, Viral Genes, Viral Genotype Genotype Genotype Humans Humans Humans Male Male Male Middle Aged Middle Aged Middle Aged Mutation Mutation Mutation Peru Peru Peru Risk Factors Risk Factors Risk Factors HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV-1 genetics HIV-1 genetics HIV-1 genetics HIV Infections blood HIV Infections blood HIV Infections blood HIV Infections drug therapy HIV Infections drug therapy HIV Infections drug therapy HIV Infections virology HIV Infections virology HIV Infections virology Treatment Outcome Treatment Outcome Treatment Outcome Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Viral Load Viral Load Viral Load Drug Resistance, Viral Drug Resistance, Viral Drug Resistance, Viral Anti-Retroviral Agents Anti-Retroviral Agents Anti-Retroviral Agents Young Adult Young Adult Young Adult Health Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatment Life Sciences Immunology and Microbiology Virology HIV Research and Treatment Health Sciences Medicine Infectious Diseases HIV/AIDS Research and Interventions |
| url | https://pubmed.ncbi.nlm.nih.gov/30560685 https://www.ncbi.nlm.nih.gov/pmc/articles/6360394 https://hdl.handle.net/20.500.15037/925 |
| work_keys_str_mv | AT jaimesoria pretreatmenthivdrugresistanceandvirologicoutcomestofirstlineantiretroviraltherapyinperu AT raquelmugruza pretreatmenthivdrugresistanceandvirologicoutcomestofirstlineantiretroviraltherapyinperu AT mollylevine pretreatmenthivdrugresistanceandvirologicoutcomestofirstlineantiretroviraltherapyinperu AT segundorleon pretreatmenthivdrugresistanceandvirologicoutcomestofirstlineantiretroviraltherapyinperu AT jorgearevalo pretreatmenthivdrugresistanceandvirologicoutcomestofirstlineantiretroviraltherapyinperu AT eduardoticona pretreatmenthivdrugresistanceandvirologicoutcomestofirstlineantiretroviraltherapyinperu AT ingridabeck pretreatmenthivdrugresistanceandvirologicoutcomestofirstlineantiretroviraltherapyinperu AT lisamfrenkel pretreatmenthivdrugresistanceandvirologicoutcomestofirstlineantiretroviraltherapyinperu |